Wednesday, June 10, 2026

pharma Β· Neurogenic Detrusor Overactivity

Astellas Pharma

Astellas Pharma drug portfolio β€” 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

JP HQ
12,378 Employees
EMA registrant Type
Company details
Intelligence Β· Drug Pipeline

Astellas Pharma pipeline

Portfolio lens on 2 drugs and development assets β€” regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Astellas Pharma drug portfolio β€” 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

2 compounds
  1. US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist
  2. US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.

    Target
    Muscarinic acetylcholine receptor M2
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist